Production (Stage)
Ernexa Therapeutics Inc.
ERNA
$2.29
-$0.08-3.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.20M | -5.76M | -26.60M | -5.53M | -6.65M |
| Total Depreciation and Amortization | 69.00K | 68.00K | 451.00K | 578.00K | 541.00K |
| Total Amortization of Deferred Charges | -- | 3.11M | 1.23M | 474.00K | 445.00K |
| Total Other Non-Cash Items | 5.84M | 461.00K | 21.92M | 466.00K | 934.00K |
| Change in Net Operating Assets | 226.00K | -1.43M | -3.28M | 1.75M | 980.00K |
| Cash from Operations | -2.07M | -3.55M | -6.29M | -2.26M | -3.75M |
| Capital Expenditure | -- | 0.00 | -19.00K | -249.00K | -101.00K |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 0.00 | 0.00 | 4.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 0.00 | -19.00K | -249.00K | -97.00K |
| Total Debt Issued | 2.25M | 0.00 | 3.89M | 0.00 | 1.41M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4.00K | 1.14M | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | 0.00 | -8.00K | -- |
| Other Financing Activities | -- | -135.00K | 0.00 | -14.00K | -20.00K |
| Cash from Financing | 2.25M | 1.01M | 3.89M | -22.00K | 1.39M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 189.00K | -2.54M | -2.42M | -2.53M | -2.46M |